Does PRALSETINIB Cause Tumour marker increased? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Tumour marker increased have been filed in association with PRALSETINIB (Gavreto). This represents 0.4% of all adverse event reports for PRALSETINIB.
5
Reports of Tumour marker increased with PRALSETINIB
0.4%
of all PRALSETINIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Tumour marker increased From PRALSETINIB?
Of the 5 reports, 2 (40.0%) required hospitalization.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PRALSETINIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does PRALSETINIB Cause?
Death (126)
Fatigue (104)
Asthenia (96)
Off label use (92)
Hypertension (89)
Disease progression (85)
Anaemia (80)
Diarrhoea (79)
Pyrexia (75)
White blood cell count decreased (74)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which PRALSETINIB Alternatives Have Lower Tumour marker increased Risk?
PRALSETINIB vs PRAMIPEXOLE
PRALSETINIB vs PRAMIPEXOLE\PRAMIPEXOLE
PRALSETINIB vs PRAMLINTIDE
PRALSETINIB vs PRASTERONE
PRALSETINIB vs PRASUGREL